Medikamentenvergleiche
Linagliptin vs. Insulin Degludec
Compare Linagliptin (Tradjenta) and Insulin Degludec (Tresiba) for type 2 diabetes. Oral vs insulin: efficacy, hypoglycemia risk, weight effects.
Für diese Seite sind keine Vergleichsdimensionen verfügbar.
Klinischer Kontext
This comparison arises when intensifying type 2 diabetes therapy beyond metformin, choosing between adding an oral DPP-4 inhibitor or starting basal insulin.
Fazit
Linagliptin suits most as a convenient oral add-on, while insulin degludec is better when stronger glucose control is required.
Alle Medikamentenvergleiche